Abstract
Introduction
Understanding disease progression in Alzheimer’s disease (AD) awaits the resolution of three fundamental questions: first, can we identify the location of “seed” regions where neuropathology is first present? Some studies have suggested the medial temporal lobe while others have suggested the hippocampus. Second, are there similar atrophy rates within affected regions in AD? Third, is there evidence of causality relationships between different affected regions in AD progression?
Methods
To address these questions, we conducted a longitudinal MRI study to investigate the gray matter (GM) changes in AD progression. Abnormal brain regions were localized by a standard voxel-based morphometry method, and the absolute atrophy rate in these regions was calculated using a robust regression method. Primary foci of atrophy were identified in the hippocampus and middle temporal gyrus (MTG). A model based upon the Granger causality approach was developed to investigate the cause–effect relationship over time between these regions based on GM concentration.
Results
Results show that in the earlier stages of AD, primary pathological foci are in the hippocampus and entorhinal cortex. Subsequently, atrophy appears to subsume the MTG.
Conclusion
The causality results show that there is in fact little difference between AD and age-matched healthy control in terms of hippocampus atrophy, but there are larger differences in MTG, suggesting that local pathology in MTG is the predominant progressive abnormality during intermediate stages of AD development.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Alzheimer’s disease (AD) has been extensively studied using cross-sectional structural magnetic resonance imaging (sMRI) methods [1, 2]. Most studies have employed morphometric approaches [3–6] and consistently report gray matter (GM) changes in the hippocampus, entorhinal cortex (EC), and temporal lobe [1, 2, 7, 8]. Although such studies identify regions implicated in the neuropathological processes associated with AD, they can shed no light on individual change over time. To overcome this limitation, several longitudinal sMRI studies have been undertaken [9–18]. Such studies have the advantage of providing more efficient estimators of illness trajectory in terms of neuropathological progression pattern and rates of spread as the illness subsumes new territories of the neocortex. For example, the structural changes in amnesic mild cognitive impaired (aMCI) patients has been longitudinally assessed using whole-brain morphometry [9], where changing atrophy patterns have been identified as subjects progress from aMCI to AD [12]. There is evidence of a particularly rapid atrophy of the hippocampus in aMCI and AD patients in the earlier stages of the disease [16].
Typically, in the study of atrophy progression, regression methods are applied for analysis of the time-dependent data as a function of some predictor variables [19]. Application of transition models such as the Markov general linear model [20] can also be used to trace the pathology characteristic of disease progression [16]. This is a simple procedure which includes past response covariates in the model but does not include interaction terms so it cannot assess any causality feedback interactions (effective connectivity) between affected structures in the longitudinal data. Causality relationships between regions in AD are potentially important. For example, Whitwell [21] has argued that such approaches provide unique insights into region-specific variation and region-specific inter-dependencies of pathology development. To address both feed-forward and feedback causality issues, feedback [19] or Granger causality (GCM) [22] models can be adopted.
The objectives of this study are to combine longitudinal sMRI data with a causality analysis in a large population of prodromal AD and AD patients to address three questions in disease progression. First, what is the pattern of neuropathological expansion in AD and which regions show earliest disease effects? Previous studies implicate regions of the hippocampus and EC early in the course of illness, with later pathology extending to include medial temporal lobe (MTL) and middle temporal gyrus (MTG) structures [12, 23]. However, these findings are based on relatively small subject groups, so typicality, in terms of disease progression, is uncertain. In this large-scale study, we test the hypothesis that this progression pattern in AD is indeed characteristic of the disease course. The second question we seek to answer is, whether the atrophy rates (GM loss) noted in AD is similar or different across affected regions? This includes analysis of hemisphere-related pathological asymmetry. For example, recent AD studies which estimated the atrophy rate based on brain regional volume [15, 24–26] suggest that hippocampus atrophy may be faster than that seen in MTG; we anticipate that analysis of this large longitudinal population will confirm this finding. Third, a fundamental question is whether patterns of atrophy across affected regions are inter-dependent or independent, i.e., is there any causality relationship between for example hippocampus atrophy in earlier stages of disease and the MTG atrophy present at later stages of the disease? Previous work by Nestor and colleagues [10] suggest that the degree and rate of pathology development may be a local phenomenon rather than “inheriting” pathology from other more remote structural entities. We predict that progressive hippocampal changes will be predominantly influenced by a previous state of atrophy in this structure. However, in relation to other temporal regions, we hypothesize that, although these will again be primarily influenced by their local atrophy characteristics, there will also be an additional influence from the hippocampus condition on this progression.
Materials and methods
Subjects
The data were obtained from the Open Access Structural Imaging Series (OASIS, http://www.oasis-brains.org/) database, generously contributed by Dr. Randy Buckner [27, 28]. The data acquisition conformed to The Code of Ethics of the World Medical Association (Declaration of Helsinki), printed in the British Medical Journal (18 July 1964). One hundred and fifty subjects (63 males) aged 60 to 96 were included in the study. Each subject was scanned on two or more visits. All scan intervals (from initial scan) were rounded to the nearest year e.g., a scan occurring less than 6 months post-initial scan would be classified as year 0 while a scan occurring 6 months or more later would be classified as year 1 and so on. The analysis was made up of 373 imaging sessions. For each subject at each visit, three or four individual T1-weighted MRI scans are included in the database. The subjects were all right-handed and included both men and women. All subjects were classified according to accepted guidelines using the clinical dementia rating scale (CDR), a key scale in determining dementia of the Alzheimer type [29]. Seventy-two of the recruited subjects were designated as normal aging (age matched healthy controls) throughout the study. Sixty-four others were classified as suffering from some stage of dementia of the AD type at first attendance and remained so classified at subsequent scans, including 51 individuals diagnosed with very mild (CDR = 0.5) and 13 mild to moderate (CDR > 0.5) dementia of the AD type. Fourteen classified as normal aging at first presentation were subsequently reclassified as suffering some level of dementia consistent with AD on one or more later visits. For the purposes of this longitudinal morphometric comparison, we regarded these 14 converters as AD subjects. The mean age of the AD patients (64 + 14 subjects; 40 males) was 77.0 (±7.2), and the mean age of the healthy control subjects (19 males) was 77.1(±8.1). The age of the AD patients was not significantly different from that of the controls (t = 0.1014 nonsignificant at p < 0.05). The mean mini-mental state examination (MMSE) score was 25.4 (±4.4) for the AD patients and 29.2 (±0.9) for control subjects. The MMSE score of the controls was significantly different from that of the AD patients (t = 11.6805, p < 0.05). The AD subjects were clinically diagnosed with very mild to moderate AD: CDR = 0.5, very mild dementia; CDR = 1, mild dementia; CDR = 2, moderate dementia [30]. The CDRs of the 78 subjects in the AD group are between 0.5 and 2 (only two subjects had a CDR of 2).
Structural MRI acquisition
All sMRI were collected with a 1.5-T scanner (Vision, Siemens, Erlangen, Germany). Structural images were acquired with a transmit–receive circularly polarized head coil, and a T1-weighted magnetization prepared rapid gradient-echo sequence (TR [recovery time] = 9.7 ms; TE [echo time] = 4 ms; flip angle = 10°), giving 128 (gap 1.25 mm) sagittal slices of 256 × 256 image voxels with a voxel size of 1 × 1 × 1.25 mm. No neuroimaging evidence of focal lesions such as brain tumors was found, and neither cortical nor subcortical vascular lesions were visible on the structural images.
Structural MRI processing
The pipeline for the sMRI data processing is shown in Fig. 1. For each subject visit, three or four individual T1-weighted MRI scans were averaged to increase the signal-to-noise ratio. These averaged structural images of each of the 373 sessions were registered to the conventional affine Talairach space [31] by the mritotal function provided by MINC tools software (http://noodles.bic.mni.mcgill.ca/ServicesSoftware/HomePage) to improve the registration in FSL (http://www.fmrib.ox.ac.uk/fsl/). If a scan was misregistered (each image was checked visually) by mritotal, then the manual control point registration method was performed using register software from MINC tools. The averaged structural images were re-sampled to 2 × 2 × 2 mm (FSL can only process the data with maximum image resolution of 2 × 2 × 2 mm) and transformed to Talairach space for FSL-VBM software analysis (for details: http://www.fmrib.ox.ac.uk/fsl/fslvbm/index.html) by using a mincresample function with trilinear interpolation in MINC tools. Then FSL-VBM pre-processing (Fig. 1 solid line blocks) was conducted as follows. First, the BET method [32] was employed to extract the brain (cut the skull from whole image) from the averaged and re-sampled structural image for each of the 373 image sessions. Next, non-uniformity correction was carried out, and FAST4 [33] was used to segment tissues according to their type. The segmented GM partial volume images were then aligned to the Montréal Neurological Institute (MNI) standard space (MNI152) by applying the affine registration tool FLIRT [34] and nonlinear registration FNIRT methods, which use a B-spline representation of the registration warp field [35]. The registered images (before smoothing) were averaged to create a study specific template, and the native GM images were then nonlinearly re-registered to the template image. The registered GM partial volume images were then modulated (to correct for local expansion or contraction) by dividing them by the Jacobian of the warp field. The segmented and modulated images were then smoothed with an isotropic Gaussian kernel with a full-width-at-half-maximum = 12 mm using SPM5 (http://www.fil.ion.ucl.ac.uk/spm/) with VBM 5.1 (http://dbm.neuro.uni-jena.de/vbm/vbm5-for-spm5/) software packages (SPM 5-VBM 5.1). The result images are projected from the MNI space to the Talairach space.
For the longitudinal VBM comparison, if the subject had two visits (visit 1 was denoted as time point 1 and visit 2 was represented as time point 2), we used all sMRI data from both visits for the comparison. If the subject had three visits, we only used the first visit as time point 1 and last visit as time point 2 for the VBM comparison. If the subject had four or five visits, we used the first two visits to create an average of GM concentration as time point 1, and the last two visits to create an average GM concentration for time point 2 for the VBM comparison. The interval between time points 1 and 2 was always at least 1 year (only one subject (subject OAS2_0048) has two MRI scans within 1 year). The date of the scan information (“oasis_longitudinal.csv” file) of the MRI scan can be downloaded from the OASIS website (http://www.oasis-brains.org/). It should be noted that in our VBM analysis, both AD and AD converters have been combined to form the patient population. Two separate VBM analyses were conducted: the first compared GM concentration between normal aging subjects with AD patients at time point 1 and the second VBM repeated the comparison for time point 2. A whole-brain voxel-based two-sample t test analysis (equal variance) was performed (SPM 5-VBM 5.1). All the default parameters for the t test were accepted except the absolute threshold for the GM which was set to 0.01. The significance threshold with the family-wise error (FWE) [36] corrected threshold was set to be p < 0.05.
To help localize GM differences, the 116 regions specified in the automated anatomical labeling (AAL) template [37] were used to label regions in the resulting statistical maps. Finally, the atrophy rate within each of the identified regions of GM loss was estimated using a robust linear regression method [38] at the group level (second-level analysis) [39].
To study the effective connectivity between the hippocampus and MTG, a network as shown in Fig. 2 was constructed. Then, a GCM (Appendix 1) with feedback was developed for each subject. For the causality analysis, only the subjects who had at least three visits were used in the analysis, including 20 AD subjects and 34 healthy controls. The GCM needs at least three visits to solve the equation (Eq. A2 in Appendix) for each individual subject. After deriving the model and its parameters, Granger causality inferences (Appendix 2) were employed, and an F test was applied to test the causality inference for each subject (see Appendix 3). For the second-level analysis [40], a mixed effect model was used to compare causality in the control subjects and AD patients (see Appendix 4).
Results
Localization of cortical atrophy with longitudinal VBM (to address question 1)
The results of the VBM analysis investigating regions of GM concentration change in the AD patients compared to normal aging participants is shown in Fig. 3 at time points 1 (Fig. 3a) and 2 (Fig. 3b). White outlines on the cortex image show the anatomical region boundaries (the edges) of the AAL template detected by the canny method from the MATLAB function edge.
The color regions on the cortex indicate regions where GM concentration was significantly reduced in AD patients. The initial GM deficits are generally bilateral, located in anterior regions of the hippocampus and entorhinal cortex (EC). Smaller regions of the MTG and temporal pole also show deficits. The figure is consistent with a regional expansion of affected areas with time, which fits with the way AD pathology is known to progressively subsume medial temporal structures. By time point 2, there is an observable progression of atrophy in the medial temporal regions. Hippocampus GM loss has also extended so that most of the structure is affected. Increased deficits were also found in the parahippocampus, MTG, and temporal pole with evidence of extension into the fusiform and parahippocampal gyri. It is also of interest to note that at time point 1, atrophy changes appear more prominent in the right hemisphere, while by time point 2, changes appear to have progressed more rapidly in the left. In addition, the full factorial model (2 × 2 ANOVA) was adopted in the VBM analysis which combines the “four groups” (two groups, two time points). We did not find significant difference between time points 1 and 2 in the AD and control group comparison. We further investigated this using a two sample t test VBM by setting the contrast matrix to [1 0 −1 0] and [0 1 0 −1] in full factorial model (the results were exactly the same and not reproduced here). These results confirmed a GM difference between the AD patients and their normal aging counterparts at both time points, predominantly located in the hippocampus and MTG areas. However, the group by time point interaction contrast failed to uncover any significant voxels. This is unexpected and counter intuitively suggests that over the test period, GM changes in both groups were somewhat parallel. However, the analysis method uncouples intra-subject relationships in GM concentration over time, and it is possible that this permits inter-subject variability, which is increased at time point 2 to mask a group influence on differences in rate of atrophy progression.
Atrophy rate estimation in the affected regions (to address question 2)
To further study the atrophy changes in regions showing significant reduction in GM concentration, we employed regional masks to isolate the primary affected regions (hippocampus, MTG) and averaged the GM concentration within these regions for each subject. The first scan was used as the baseline, and subsequent GM changes were estimated by calculating the proportional change (subtracting the first baseline image). Robust linear regression methods [38] were applied to calculate the atrophy rate. The variation in GM concentration over time for the healthy aging and patient groups (patients with dementia at first scan and converters are shown separately) in the hippocampus and MTG are shown in Fig. 4.
The data show that there is a considerable amount of variation across the AD subjects in terms of yearly rate of GM atrophy for both hippocampus and MTG structures, but it is typically 1% for hippocampus and 0.5% for MTG. These rates are, respectively, two times and five times greater than rates of atrophy measured in the normal aging controls, both differences are statistically significant when compared to their normal aging counterparts (p < 0.05; Fig. 4c). It is also important to note that in the comparison of the atrophy rates between the AD converters (we used seven converted subjects who have at least three longitudinal scans in Fig. 4) and matched controls, no significant difference was noted between the hippocampal atrophy rate; however, the atrophy rate was significantly higher in the MTG for the converter group (p < 0.05) suggesting over the period of conversion GM changes in this region are particularly prominent. This is confirmed by the fact that atrophy rates between hippocampus and MTG also significantly differ from one another in this group (p < 0.05).
Table 1 and Fig. 5 contain results for the asymmetry analysis. Although Fig. 5 suggests a change in the relative GM volume (right relative to left hemisphere) in the hippocampus of AD patients compared to controls, this was not confirmed statistically. A two-sample t test showed no significant difference between the asymmetry measures (for either the hippocampus or MTG) between the AD patients and healthy controls, suggesting that the relative (right/left) GM volume in the structures were not altered by disease (Table 1). A hemisphere related asymmetry in GM concentration (Left > Right) was observed for both the hippocampus and MTG which is more marked in the MTG in both populations (Table 1 and Fig. 5). Though it appears atrophy rates are different in the two structures and different in AD and normal aging, this divergence is not profound enough in the present dataset to show statistical difference between groups. This may be because AD subjects are generally in the mild to moderate stage of disease.
Effective connectivity abnormality in AD (to address question 3)
To estimate the parameters within the GCM to test for effective connectivity (Eq. A2 in Appendix), we required at least three longitudinal scans, which reduced our analysis population to 20 AD subjects and 34 controls. Because of brain symmetry (Fig. 5 and Table 1) and to increase numerical stability, left and right hemispheres were combined in the solution of the GCM equation (Eq. A3 in Appendix 1). A two-connection network was constructed (Fig. 2), and the parameters for the network were calculated (see Appendixes 1 and 2); an F statistic (Appendix 3) was used to assess significance of inter-region influence (causality). Subsequently, a two-sample t test was employed for group comparisons. The group averaged model for the AD subjects was:
where y 1(t) represents the GM concentration in hippocampus of the AD subjects localized as shown in Fig. 3b; y 2(t) denotes the GM concentration in MTG of the AD subjects. e 1(t) and e 1(t) are random noise. Similarly, the averaged model for the age matched healthy control subjects was:
F tests values for all the causality (trimmed mean values) are given in Table 2 and Fig. 6a. Figure 6b shows the corresponding coefficients of the feedback model (Eqs. 1, 2, 3, and 4). A mixed effect model (Appendix 4) was employed for the second-level (between-subjects) analysis [40].
Analysis of variance confirms consistent causality relationships between time points 1 and 2 for both structures for both groups (F(1,52) = 11.152, p < 0.01). The analysis failed to indicate any group interaction suggesting that this relationship is similar in both the AD and control subjects. The analysis also confirmed a weaker but still significant relationship between regions (F(1,52) = 4.365, p < 0.05). This suggests that later structural GM concentrations are better predicted by previous concentrations within the same structure and not by a feedback or feed-forward mechanism between structures. There was no evidence of a group interaction suggesting that this inter-structural relationship was not affected by AD (Fig. 6). The difference in causality indices between intra-structural and inter-structural causality was also confirmed in the analysis (F(1,52) = 20.357, p < 0.001), confirming stronger causality relationships within structures rather than between structures. Several post hoc analyses were also performed. First, we tested to see if there was any evidence of the intra-structural causality found for the hippocampus and the MTG being of differing magnitude (independent of group). The results showed that the causality was greater within the hippocampus than in the MTG (t(53) = 4.083, p < 0.001). A second analysis to compare directionality effects in inter-structural causality (hippocampus to MTG compared to MTG to hippocampus) confirmed a greater influence of the hippocampus on the MTG than the reverse situation (t(53) = −4.286, p < 0.001). To follow this up, we tested to see if the group had any effect on these general relationships. Similar t tests applied on a group basis produced identical results. Suggesting that the causality differences noted above applied equally to both AD and control subjects.
The causality analyses not only confirm relationships between previous and current atrophy states within the hippocampus and MTG but also evidence of temporal relationships between atrophy states across these structures. It is clear from the results that for both the hippocampus and MTG, local changes in GM concentration are the best predictors of future changes. It is also clear that hippocampus atrophy is a better predictor of MTG changes over time than the reverse. Group comparisons of causality indices showed no statistically significant differences. This suggests that the general atrophy patterns encountered in AD are superimposed upon the same causal relationships or linkages upon which normal aging atrophy changes are founded and do not perturb these relationships per se. However, the large increases in statistical variation in the causality data (Fig. 7 and Table 3) for the patient group does suggest that causality relationships are less consistent and may be breaking down in AD subjects compared to their healthy aging counterparts. However, there is no evidence of a uniform trajectory for this breakdown. This may also explain the lack of an observable statistical difference in the group by time point interaction contrast in the VBM analysis.
The coefficient distribution across subjects in the feedback models (Eqs. 1, 2, 3, and 4) are shown in Fig. 7 and Table 3. From Figs. 6b, 7, and Table 3 (mean and standard deviation of the coefficients), it can be seen that coefficients in the MTG feedback model have a much greater scatter (larger standard derivation) than the hippocampus feed-forward model in both control and AD patients. The lower variability of the causal coefficients within each structure compared to between each structure across the subjects is clearly illustrated in this figure (Fig. 6b). The results of the preceding sections can be summarized as set out in Table 4 below.
Discussion
In this large study, longitudinal VBM methods [5, 9, 41, 42] were employed to map the progression of GM changes in AD. This was done by comparing sMRI images collected at initial referral with images acquired on a second later occasion (one or more years later). The majority of the population studied were considered to be at an early stage in illness progression at first scan as 51 of 64 (80%) had a CDR = 0.5 consistent with a very mild stage of the disease of AD type. In addition, a further 14 appeared to be prodromal at this stage. Therefore, in general, time point 1 in the analysis can be considered to represent neuropathology near clinical onset of AD.
Two key regions of atrophy were located bilaterally in the hippocampus and MTG. Absolute qualification of the atrophy rate in these regions was employed to assess whether there were rate differences in GM concentration in these areas. Finally, we carried out a causality analysis to determine patterns of association between the time courses of atrophy accumulation in the hippocampus and MTG regions. Results indicate that in AD, GM loss is extensive; involving large regions of the hippocampus, parahippocampus, MTG, and EC, and so it is not simply loss of effective connectivity in terms of known structural connections which has been reported in some diffusion tensor image studies [43–46]. Further, progression of the disease is fairly rapid and encompasses progressive changes in multiple regions.
Correspondence with previous longitudinal studies
Our results concur with the findings of pathological staging schemes in AD [12, 23, 24], namely that primary neuropathology is first identified in AD in the EC and hippocampus regions (transentorhinal stages I and II), before subsuming temporal lobe structures such as the MTG (limbic stages III and IV). Secondly, the hippocampus showed progressive atrophy throughout the disease course. This is in agreement with other studies [12, 16, 17]. Our results also show that the atrophy rates in the hippocampus were faster than in the MTG in both AD and normal aging subjects, but with a faster rate of change in the AD patients (Fig. 4a). This supports the observation that atrophy rates accelerate as individuals progress further into the disease [24]. It is worthwhile to mention that the unit of atrophy rate in the study is absolute (in proportion). The advantage of using such an absolute unit is that it is straightforward to observe the group decline rate and compare the individual rates across subjects at the same time (Fig. 4). The limitation of this method is that it is unable to quantify the hippocampus volume size change with time. It is interesting to note that the study failed to find any involvement of the posterior cingulate at both time points. This region has previously been implicated in AD pathology [9, 47]. This is in line with some previous work [12] where posterior cingulate cortex abnormality in AD was not detected. The reason for the discrepancy may be because most of our subjects were in the earlier stages of AD (CDR = 0.5); cingulate involvement may, therefore, not have been sufficient to be properly identified. The use of the conservative FWE correction method [36] to correct for multiple comparisons in the VBM analysis may also have contributed in this respect.
Effective connectivity in this study
Although functional [48–54] and structural [49] connectivity abnormalities have been reported in AD, the causality issue [10, 21, 55] of regional atrophy in AD based on longitudinal structural MRI has received little attention. By this, we mean that the temporal pattern of atrophy development, for example, in structures such as the hippocampus, which display earlier evidence of pathology, predict or modulate the way pathology appears and develops in other affected regions as the disease takes hold. Unlike most previous functional connectivity studies which used functional MRI with task-free (resting-state) conditions [49, 53, 54]; we used the GM concentration extracted from the sMRIs to study the effective connectivity. The advantage of this approach is that it has better spatial resolution and, thus, provides increased confidence in localization of the affected brain regions in AD. Furthermore, the functional connectivity approach [56] relies on the correlation; therefore, it is limited in that it cannot address the question of causality between different brain regions. We employed a causality model similar to the work of Granger [22] which is a feedback model [19] and was based on the proposal that there were causality relationships between hippocampus and MTG GM losses over time. This method relied on local current GM values in these regions having a causality relationship with their own past. This model, also named the Markov chain model [20], has been applied to study AD progression previously [16]. We found there were significant influences of atrophy changes over time in the hippocampus on temporal patterns of MTG GM change and vice versa in both AD and their normal age-matched controls. We found there was stronger feed-forward from the hippocampus to MTG than feedback from the MTG to hippocampus (Table 1). This suggests that the changes in and around the hippocampus act as an influence for the way AD engulfs other regions of the temporal lobe. Having said this, the finding that the autoregressive analysis provided by far the best causality linkages shows that in fact the best overall predictors of future change in both the hippocampus and MTG GM was in fact their previous atrophy condition. This result supports the findings of previous studies [10] suggesting that local pathology is an important variable for the progression of the disease. It must be noted that there is evidence that MTG local pathology is a weaker predictor of its future condition than the hippocampus. This might implicate stronger network influences from connected regions such as the hippocampus.
Advantages and limitations of the method
The strength of the study is, first and foremost, the involvement of a relatively large number of subjects and scans. We used all the 373 cross-sectional MRI scans from OASIS. Furthermore, our method is primarily a longitudinal one, which overcomes the limitation of cross-sectional designs. In addition, in the sMRI data pre-processing stage, we combined three widely used software packages (MINC tools, FSL, and SPM) for VBM data analysis. One major difference between FSL-VBM 1.1 and SPM 5-VBM 5.1 is that FSL-VBM 1.1 uses a permutation test for the statistical comparison in the last step of VBM analysis, while SPM 5-VBM 5.1 uses a two-sample t test. The permutation results often include a lot of abnormal regions in AD compared with the two-sample t test method [8]. To get conservative values, we chose SPM 5-VBM 5.1 and adopted a two-sample t test for the final group comparison. This enables us to use the strengths of both software packages in the analysis. Lastly, in the regression analysis (Figs. 4a, b, and 5), a robust linear regression method was adopted to overcome the limitation of outlier influence on the atrophy rates estimations.
Several limitations in this study should be noted. Firstly, the time interval between the first and second time points is not the same for all the subjects. This will have the effect of increasing variability of atrophy rate across subjects as smaller intervals will tend to show lower rates and longer intervals higher rates in a two-level (time points 1, 2) analysis. Also, there was considerable variation in subject age at initial recruitment. The analysis makes the assumption that atrophy rate will not be affected by this. This allows us to combine the patients with AD at study onset with those who converted in the study period. However, there is some evidence in this study, from comparisons between AD and AD converter subjects, that rate changes for example in the MTG may be more rapid in earlier stages than later on. Combining these two sets of data for the VBM analysis may have had some effects on results. Although a previous study [57] suggested atrophy rate was linear during the aging processing in healthy subjects, another study [24] showed evidence that atrophy rates may fluctuate in different stages of AD.
Another point to mention is that, unavoidably, patients recruited were not all at the same stage of disease. Although the majority of patients were classified as very mild dementia of AD type there remains the problem as to whether atrophy rate in AD holds a linear or nonlinear course as patients become more impaired.
We employed causality based on the feedback model for the longitudinal dataset. Although there has been no universally accepted definition of causality, it is commonly accepted that the notion of causality of two events describes to what extent one event is caused by the other [58]. In the analysis, most of the subjects have three time points (three visits); more longitudinal scans would be needed for more accurate estimates of the causality relationships. This is because the coefficients can contain estimation bias [59] for short time series, especially for the auto-correlation models. Although we combined the left and right hemisphere data to reduce the estimation bias, this only partially offsets the lack of time points in the series. Finally, for the causal model used in this study, we only included linear influences, nonlinear influences were neglected. A nonlinear method [60] with more connected regions and time points could be used to study effective connectivity in future studies in attempts to more fully explore causality relationships.
Finally, it should be pointed out that our causality analysis is based on the averaged concentration of GM in regions of hippocampus and MTG which of course assumes regular atrophy rates across each of the structures; this assumption may not be correct. There is some evidence for example that not all regions of the hippocampus are affected equally in AD as the disease develops with suggestions of an anterior to posterior progression [12].
Conclusion
In conclusion, this investigation provides the following answers to the three posited questions from the data used in this analysis: (1) what is the pattern of neuropathological expansion in AD? In the early phase of AD, progression appears to encompass the hippocampus and EC regions, with development of increasing pathology in other regions particularly the MTG region over time. (2) Are there similar atrophy rates within affected regions in AD? Affected regions appear to have different atrophy rates, and our results suggest faster atrophy rates in the hippocampus over several years near illness onset. (3) Is there evidence of causality relationships between different affected regions in AD progression? The data suggest that local pathology is important for AD progression in affected regions, but there is evidence that magnitude of hippocampal changes may be a factor for increasing MTG abnormality in AD. Interestingly, similar patterns of atrophy progression and causality relationships were found in the normal aging subjects. This suggests that the pathological processes underpinning AD amplify brain changes present during the normal aging process.
References
Chetelat G, Degranges B, Sayette VDL, Viader F, Eustache, Baron JC (2002) Mapping grey matter loss with voxel-based morphometry in mild cognitive impairment. NeuroReport 13:1939–1943
Karas G, Burton EJ, Rombouts SARB, Schijndel RAV, O'Brien JT, Scheltens PH, McKeith IG, Williams D, Ballard C, Barkhof F (2003) A comprehensive study of grey matter loss in patients with Alzheimer's disease using optimized voxel-based morphometry. Neuroimage 18:895–907
Ashburner J, Friston KJ (2000) Voxel-based morphometry-the methods. Neuroimage 11:805–821
Davies RR, Scahill VL, Graham A, Williams GB, Graham KS, Hodges JR (2008) Development of an MRI rating scale for multiple brain regions: comparison with volumetrics and with voxel-based morphometry. Neuroradiology 51:491–503
Kakeda S, Korogi Y (2010) The efficacy of a voxel-based morphometry on the analysis of imaging in schizophrenia, temporal lobe epilepsy, and Alzheimer's disease/mild cognitive impairment: a review. Neuroradiology 52:711–721
Takao H, Abe O, Ohtomo K (2010) Computational analysis of cerebral cortex. Neuroradiology 52:691–698
Hirata Y, Matsuda H, Nemoto K, Ohnishi T, Hirao K, Yamashita F, Asada T, Iwabuchi S, Samejima H (2005) Voxel-based morphometry to discriminate early Alzheimer's disease from controls. Neurosci Lett 382:269–274
Li X, Messé A, Marrelec G, Pélégrini-Issac M, Benali H (2010) An enhanced voxel-based morphometry method to investigate structural changes: application to Alzheimer’s disease. Neuroradiology 52:203–213
Chetelat G, Landeau B, Eustache F, Mezenge F, Viader F, de la Sayette V, Desgranges B, Baron JC (2005) Using voxel-based morphometry to map the structrual changes associated with rapid conversion in MCI: A longitudinal MRI study. Neuroimage 27:934–946
Nestor PJ, Schetens P, Hodges JR (2004) Advances in the early detection of Alzheimer's disease. Nat Rev Neurosci 7:s34–s41
Fox NC, Warrington EK, Freeborough PA, Hartikainen P, Kennedy AM, Stevens JM, Rossor MN (1996) Presymptomatic hippocampal atrophy in Alzheimer's disease: a longitudinal MRI study. Brain 119:2001–2007
Whitwell JL, Przybelski SA, Weigand SD, Knopman DS, Boeve BF, Petersen RC, Jack CR Jr (2007) 3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease. Brain 130:1777–1786
Chan D, Janssen JC, Whitwell JL, Watt HC, Jenkins R, Frost C, Rossor MN, Fox NC (2003) Change in rates of cerebral atrophy over time in early-onset Alzheimer's disease: longitudinal MRI study. Lancet 362:1121–1122
Schott JM, Fox NC, Frost C, Scahill RI, Jassen JC, Chan D, Jenkins R, Rossor MN (2003) Assessing the onset of structural change in familial Alzheimer's disease. Ann Neurol 53:181–188
Fox NC, Schott JM (2004) Imaging cerebral atrophy: normal ageing to Alzheimer's disease. Lancet 363:392–394
Schuff N, Woerner N, Boreta L, Kornfield T, Shaw LM, Trojanowski JQ, Thompson PM, Jack CR Jr, Weiner MW (2009) MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain 132:1067–1077
Ridha BH, Barnes J, Barlett JW, Godolt A, Pepple T, Rossor MN, Fox NC (2006) Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study. Lancet Neurol 5:824–834
Schill RI, Frost C, Jenkins R, Whitwell JL, Rossor MN, Fox NC (2003) A longitudinal study of brain volume changes in normal aging using serial registered magnetic resonance imaging. Arch Neurol 60:989–994
Zeger SL, Liang KY (1991) Feedback models for discrete and continuous time series. Stat Sin 1:51–64
Diggle PJ, Heagerty P, Liang KY, Zeger S (2003) Analysis of longitudinal data, 2nd edn. Oxford University Press, Oxford
Whitwell JL (2008) Longitudinal imaging: change and causality. Curr Opin Neurol 21:410–416
Granger C (1969) Investigating causal relations by econometric models and cross-spectral methods. Econometrica 37:424–438
Braak H, Braak E (1996) Evolution of the neuropathology of Alzheimer's disease. Acta Neurol Scand Suppl 165:3–12
Jack CR Jr, Weigand SD, Shiung MM, Przybelski SA, O'Brien PC, Gunter JL, Knopman DS, Boeve BF, Smith GE, Petersen RC (2008) Atrophy rates accelerate in Amnestic mild cognitive impairment. Neurology 70:1740–1752
Jack CR Jr, Shiung MM, Gunter JL, O'Brien PC, Weigand SD, Knopman DS, Boeve BF, Ivnik RJ, Smith GE, Cha RH, Tangalos EG, Petersen RC (2004) Comparison of different MRI atrophy rate measures with clinical disease progression in AD. Neurology 62:591–600
Resnick SM, Pham DL, Kraut MA, Zonderman AB, Davatzikos C (2003) Longitudinal magnetic resonance imaging studies of older adults: a shrinking brain. J Neurosci 23:3295–3301
Marcus DS, Fotenos AF, Csernansky JG, Morris JC, Buckner RL (2009) Open access series of imaging studies: longitudinal MRI data in nondemented and demented older adults. J Cog Neurosci 22(12):2677–2678
Marcus DS, Wang TH, Parker J, Csernansky JG, Morris JC, Buckner RL (2007) Open Access Series of Imaging Studies (OASIS): cross-sectional MRI data in young, middle aged, nondemented, and demented older adults. J Cog Neurosci 19:1498–1507
Morris JC (1997) Clinical dementia rating: A reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogenatrics 9(suppl 1):173–176
Morris JC (1993) The clinical dementia rating (CDR): Current version and scoring rules. Neurology 43:2412b–2414b
Talairach J, Tournoux P (1998) Coplanar stereotaxic atlas of the human brain. Thieme, Stuttgart
Smith SM (2002) Fast robust automated brain extraction. Hum Brain Mapp 17:143–155
Zhang Y, Brady M, Smith SM (2001) Segmentation of brain MR images through a hidden Markov random field model and the expectation maximization. IEEE Trans Med Imag 21:45–47
Jenkinson M, Smith SM (2001) A global optimisation method for robust affine registration of brain images. Med Image Anal 5:143–156
Rueckert D, Sonda LI, Hayes C, Hill DLG, Leach MO, Hawkes DJ (1999) Non-rigid registration using free-form deformations: application to breast MR images. IEEE Trans Med Imag 18:712–721
Nichols TE, Hayasaka S (2003) Controlling the familywise error rate in functional neuroimaging: a comparative reviews. Stat Meth Med Res 12:419–446
Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, Mazoyer B, Joliot M (2002) Automated anatomical labelling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 15:273–289
Huber PJ (1981) Robust statistics. Wiley, Hoboken
Bryk AS, Raudenbush SW (1992) Hierarchical linear models: applications and data analysis methods. Sage, New Delhi
Sullivan LM, Dukes KA, Losina E (1999) Tutorial in biostatistics: An introduction to hierarachical linear modelling. Statist Med 18:855–888
Draganski B, Gaser C, Busch V, Schuierer G, Bogdahn U, May A (2004) Changes in grey matter induced by training. Nature 427:311–312
Draganski B, Gaser C, Kempermann G, Kuhn HG, Winkler J, Buchel C, May A (2006) Temporal and spatial dynamics of brain structure changes during extensive learning. J Neurosci 26:6314–6317
Salat DH, Tuch DS, van der Kouwe AJW, Greve DN, Pappu V, Lee SY, Hevelonea ND, Zalet AK, Growdon JH, Corkin S, Fischl B, Rosasa HD (2010) White matter pathology isolates the hippocampal formation in Alzheimer's disease. Neurobiol Aging 31:244–256
Zhang Y, Schuff N, Du AT, Rosen HJ, Kramer JH, Gorno-Tempini ML, Miller BL, Weiner MW (2009) White matter damage in frontotemporal dementia and Alzheimer's disease measured by diffusion MRI. Brain 132:2579–2592
Fellgiebel A, Wille P, Muller MJ, Winterer G, Scheurich A, Vucurevic G, Schmidt LG, Stoeter P (2004) Ultrastructural hippocampal and white matter alterations in mild cognitive impairment: a diffusion tensor imaging study. Dement Geriatr Cogn Disord 18:101–108
Muller MJ, Greverus D, Dellani PR, Weibrich C, Wille PR, Scheurich A, Stoeter P, Fellgiebel A (2005) Functional implications of hippocampal volume and diffusivity in mild cognitive impairment. Neuroimage 28:1033–1042
Chetelat G, Villain N, Desgranges B, Eustache F, Baron JC (2009) Posterior cingulate hypometabolism in early Alzheimer's disease: what is the contribution of local atrophy versus disconnection? Brain 132:1–2
Vincent JL, Snyder AZ, Fox MD, Shannon BJ, Andrews JR, Raichle ME, Buckner RL (2006) Coherent spontaneous activity identifies a hippocampal-parietal memory network. J Neurophysiol 96:3517–3531
Seeley WM, Crawford RK, Zhou J, Miller BL, Greicius MD (2009) Neurodegenerative diseases target large-scale human brain networks. Neuron 62:42–56
Haan WD, Pijnenburg YL, Strijers RLM, Made YVD, Flier WMVD, Scheltens P, Stam CJ (2009) Functional neural network analysis in frontotemporal dementia and Alzheimer's disease using EEG and graph theory. BMC Neurosci 10:1–12
Stam CJ, Haan WDE, Daffertshofer A, Jones BF, Manshanden I, Van Cappellen V, Van Walsum AM, Montez T, Verbunt JPA, de Munck JC, Van Dijk BW, Berendse HW, Scheltens P (2009) Graph theoretical analysis of magnetoencephalographic functional connectivity in Alzheimer's disease. Brain 132:213–224
Celone K, Calhoun V, Dickerson B, Atri A, Chua EF, Miller SL, DePeau K, Rentz DM, Selkoe DJ, Blacker D, Albert MS, Sperling RA (2006) Alterations in memory networks in mild cognitive impairment and Alzheimer's Disease: an independent component analysis. J Neurosci 26:10222–10231
Supekar K, Menon V, Rubin D, Musen M, Greicius MD (2008) Network analysis of Intrinsic functional brain connectivity in Alzheimer's Disease. PLoS Comput Biol 4:1–11
Greicius MD, Srivastava G, Reiss A, Menon V (2004) Default-mode network activity distinguishes Alzheimer's Disease from healthy aging: Evidence from functional MRI. Proc Nat Acad Sci 101:4637–4642
Lemieux L (2008) Causes, relationships and explanations: the power and limitations of observational longitudinal imaging studies. Curr Opin Neurol 21:391–392
Bullmore E, Sporns O (2009) Complex brain networks: graph theoretical analysis of structural and functional systems. Nat Rev Neurosci 10:186–198
Good C, Johnsrude IS, Ashburner J, Henson RN, Friston KJ, Frackowiak RS (2001) A voxel-based morphometric study of ageing in 465 normal adult human brains. Neuroimage 14:21–36
Faes L, Nollo G, Chon KH (2008) Assessment of Granger causality by nonlinear model identification: application to short-term cardiovascular variability. Ann Biomed Eng 36:381–395
Shaman P, Stine RA (1998) The bias of autoregressive coefficient estimators. J Am Stat Assoc 83:842–848
Li X, Marrelec G, Hess RF, Benali H (2010) A nonlinear identification method to study effective connectivity in functional MRI. Med Image Analy 14:30–38
Wernerheim C (2000) Cointegration and causality in the exports-GDP nexus: the post-war evidence for Canada. Empirical Econ 25:111–125
Oxley L, Greasley D (1998) Vector autoregression, cointegration and causality: testing for causes of the British industrial revolution. Appl Econ 30:1387–1397
Doornik J (1996) Testing vector error autocorrelation and heteroscdasticity. The Econometric Society 7th World Congress, Tokyo, 1996.
Durbin J (1970) Testing for serial correlation in least squares regression when some of the regressors are lagged dependent variables. Econometrica 38:410–421
Breslow NE, Clayton DG (1993) Approximate inference in generalized linear mixed models. J Am Stat Assoc 88:9–25
Dempster AP, Laird NM, Rubin DB (1977) Maximum likelihood from incomplete data via the EM algorithm. J Roy Stat Soc B 39:1–38
Laird NM, Lange N, Stram D (1987) Maximum likelihood computations with repeated measures: Application of the EM algorithm. J Am Stat Assoc 82:97–105
Laird NM, Ware JH (1982) Random-effects models for longitudinal data. Biometrics 38:963–974
Worsley K, Liao CH, Aston J, Petre V, Duncan GH, Morales F, Evans AC (2002) A general statistical analysis for fMRI data. Neuroimage 15:1–15
Liang KY, Zeger SL (1986) Longitudinal data analysis using generalized linear models. Biometrika 73:13–22, Neuroimage 11:805–821
Acknowledgments
This study is supported under the CNRT award by the Northern Ireland Department for Employment and Learning through its "Strengthening the All-Island Research Base" initiative. The authors thank Dr. Randy Buckner and his colleagues for making their OASIS data available to us. They were supported by Grants No.: P50 AG05681, P01 AG03991, R01 AG021910, P50 MH071616, U24 RR021382, and R01 MH56584.
Conflict of Interest
We declare that we have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Appendices
Appendix 1: AR model within subjects for effective connectivity study
For the subjects who have at least three longitudinal scans, we assume the brain GM concentration is an autoregressive (AR) function, i.e., the GM change at a later time point is related to the GM at a previous time point. This is a reasonable assumption [16], and based on this assumption, for each affected region i, we have:
where t is the time, y i (t) is current GM concentration value; y i (t − 1) is the previous GM concentration value; a i is the AR coefficient; and e i (t) is the model error (Gaussian noise). For two-connected regions, we can consider the mutual interaction between these regions (for example hippocampus and MTG as shown in Fig. 2); we thus have a GCM as follows [19, 22]:
where y 1(t) and y 2(t) are the current averaged GM concentration in hippocampus and MTG, respectively, and y 1 (t − 1), y 2(t − 1) are the corresponding previous average GM concentration in hippocampus and MTG regions as shown in Fig. 3b. If a subject has been scanned only twice over time, we cannot estimate the coefficients based on individual subjects. Equation A2 has two parameters, but two “visits” can only produce one equation. Assuming for each subject, left and right hemispheres have the same model within each subject (Fig. 5), we can build a general linear model for each subject and combine the left and right hemisphere regional GM concentration within this model, i.e. first-level analysis for Eq. A2 [39]:
where Y = [y 2,1(t), y 2,2(t), …, y 2,n(t)]′, \( n = (V - 1) \times 2 \), where V is the total number of visits (we multiply by 2 because we combine the left and right hemisphere GM concentrations within the model); X 1 = [y 1,1(t − 1), y 1,2(t − 1), …, y 1,n(t − 1)]′, X 2 = [y 2,1(t − 1), y 2,2(t − 1), …, y 2,n(t − 1)]′. X 2 represents the AR term of y 2(t), and X 1 denotes the influence from the other connected region and \( e(t) = [{e_{{2,1}}}(t),{e_{{2,2}}}(t), \cdots, {e_{{2,n}}}(t)]{}^{\prime}\sim N(0,\sigma {}^2) \). The estimated GM concentration response is:
where \( \widehat{\beta } \) can be estimated by:
and X = [X 1, X 2], and X + is the Moore–Penrose pseudoinverse of the matrix. To study the influence from MTG to hippocampus, we swap the y 2(t) and y 1(t) in Eq. A2.
Appendix 2: Granger model for the effective connectivity
Granger causality analysis [61, 62] is derived based on F statistics. For Eq. A2, the test for determining Granger causality (GC) is: (1) y 1(t) is GC of y 2(t) [61], if b 1 = 0 in Eq. A2 is not true. Given the data, we reach this conclusion if b 1 = 0 is rejected. (2) Similarly, y 2(t) is GC of y 1(t) can be investigated by reversing the input–output roles of the two series. F statistics (see Appendix 3) are developed to detect significant relations within subject, and t statistics are developed for between-subjects analysis (Appendix 4).
Appendix 3: F test (within subject)
After the covariates and their coefficients b 1 and b 2 in Eqs. A3/A4 have been estimated by the least squares method in Appendix 1 from the GM concentration response, the F test [63] is applied to test the inference of the connectivity between different regions. Accordingly from Eq. A4, we partitioned the coefficients \( \widehat{\beta } \) as: \( \widehat{\beta } = ({\widehat{\beta }_1}:{\widehat{\beta }_2}) \) and X = (X 1 : X 2), we can write this test as:
For one GM concentration response, the F test on the causality is given by [64]:
where s is the column of X 2; k is the column of X 1; n is the total number of visits minus one (multiply by 2 if combining two hemispheres within the brain). \( R{}^2 = \frac{{{\text{RS}}{{\text{S}}_0} - {\text{RSS}}}}{{{\hbox{RS}}{{\hbox{S}}_0}}} \), where RSS0 (original system when β 2 = 0, without interaction terms for the two-connection network (Fig. 2)) and RSS are the residual sums of squares (when both the AR and feedback terms exists in the system), \( {\text{RS}}{{\text{S}}_0} = (Y - \widehat{Y}){}^\prime \times (Y - \widehat{Y}) \)(under H 0); \( {\text{RSS}} = (Y - \widehat{Y}){}^\prime \times (Y - \widehat{Y}) \). Then, we apply Eq. A6 to test the influences between regions.
Appendix 4: Mixed effect model (first level: within subject)
Apart from the F test conducted within subjects, we can also inference an effect by defining a contrast matrix c and using the t statistics, we start from estimation of an effect:
j = 1,…, n, where n is the number of visits minus one (×2 if combine two hemispheres within the model in A3/A4). For example, we can select c = [0,1] at first level contrast to study the influence from MTG to hippocampus.
where \( \widehat{\sigma } = \sqrt {{r\prime r/v}} \), \( r = Y - X\widehat{\beta } \), \( v = m - {\hbox{rank}}(X) \)is the degree of freedom (df); \( m = 2(n - 1) \)is the total number of effect in Eq. A7 for two hemispheres.
Appendix 4: Mixed effect model (second level: between subjects)
For the second-level analysis, a general linear mixed model [65] was adopted, i.e.:
where E = (E 1, …, E n* )′, S = (S 1, …, S n ), and η is normally distributed with zero mean and variance \( S + \sigma_{\rm{random}}^2 \) independently for j = 1, …, n. We want to compare the effects in VBM using covariates (Z is the design matrix for comparison in the general linear model):
If we are interested in the difference between two groups, we can set \( {I_{{{n_1}}}} = \left[ {1, \cdots, 1} \right]_{{1 \times n_1^{ * }}}^{\prime;} \),\( {I_{{{n_2}}}} = \left[ {1, \cdots, 1} \right]_{{1 \times n_2^{ * }}}^{\prime;} \),\( {O_2} = \left[ {0, \cdots, 0} \right]_{{1 \times n_2^{ * }}}^{\prime;} \), and \( {O_1} = \left[ {0, \cdots, 0} \right]_{{1 \times n_1^{ * }}}^{\prime;} \). In this study, \( n_1^{ * } = 34 \)(number of controls), \( n_2^{ * } = 20 \) (number of AD subjects).
To estimate γ in Eq. A9, we first use the restricted maximum likelihood [66, 67] algorithm to estimate \( \widehat{\sigma }_{\text{random}}^2 \). In the expectation maximization algorithm [67–69], let S = diag(S 1, …, S n* ) and I be the n * × n * identity matrix (\( n{}^{ * } = n_1^{ * } + n_2^{ * } = 54 \) in this study). From (A9), we have the variance matrix of the effects vector E = (E 1 , …, E n )′:
Define the weighted residual matrix:
Starting with an initial value of \( \sigma_{{random}}^2 = {\mathbf{E}^{{\prime;}}}{\mathbf{R}_{\rm{I}}}\mathbf{E/}{v^{*}} \) based on assuming that the fixed effects variances are zero. The updated estimate is:
where p * = rank(Z). Replace \( \sigma_{\rm{random}}^{{2}} \) with \( \widehat{\sigma }_{\text{random}}^2 \) in (A11) and iterate (A11–A13) to convergence. In practice, 10 iterations appear to be enough [69]. After convergence, step (A11) is repeated with \( \sigma_{\rm{random}}^{{2}} \) by \( \widehat{\sigma }^{2}_{{{\text{random}}}} \), then the estimate of γ is:
And its estimated variance matrix is:
In the case when the variances of E are not homogeneous across the level 2 unit (for example, different scanner), Eq. A15 should be replaced by other terms [40, 70]:
Finally, effects defined by a contrasts matrix (second level, b = [1 −1] in this study for control compared to AD) b in γ can be estimated by \( E^{ * } = b\widehat{\gamma } \) with standard deviation:
The T statistic is:
with a nominal ν * df (\( v^{ * } = n{}^{*} - {\hbox{rank}}(Z) \)) can then be used to detect such an effect.
Rights and permissions
About this article
Cite this article
Li, X., Coyle, D., Maguire, L. et al. Gray matter concentration and effective connectivity changes in Alzheimer’s disease: a longitudinal structural MRI study. Neuroradiology 53, 733–748 (2011). https://doi.org/10.1007/s00234-010-0795-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00234-010-0795-1